Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer

Journal of Pathology

Volumn 190, Issue 2, 2000, Pages 150-156

  Thomas, Pascal ^a,b   Khokha, Rama ^c   Shepherd, Frances A ^b   Feld, Ronald ^b   Tsao, Ming Sound ^c,d  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Histochemistry; Invasion; Lung; Metastasis; MMP; NSCLC; Prognosis; Proteinase; TIM

Indexed keywords

COLLAGENASE; COLLAGENASE 3; GELATINASE A; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHUS MUCOSA; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033983452     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:2<150::AID-PATH510>3.0.CO;2-W     Document Type: Article

References (32)

1. Ray JM, Steiler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-2072.
2. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumour spread in non-small-cell lung carcinoma. J Nail Cancer Inst 1993; 85: 574-578.
3. Soini Y, Paakko P, Autio-Harmainen H. Genes of laminin B1 chain, α1 (IV) chain of type IV collagen, and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. Am J Pathol 1993; 142: 1622-1630.
4. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188-1194.
5. Nagakawa H, Yagihashi S. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of the lung. Jpn J Cancer Res 1994; 85: 934-938.
6. Ohori P, Yousem SA, Griffin J, et al. Comparison of extracellular matrix antigens in subtypes of bronchioalveolar carcinoma and conventional pulmonary adenocarcinoma. Immunohistochemical study. Am J Surg Pathol 1992; 16: 675-686.
7. Muller D, Breathnach R, Engelmann A, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 1991; 48: 550-556.
8. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995; 64: 355-359.
9. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 1997; 72: 556-564.
10. Fong KM, Kida Y, Zimmerman PV, Smith PJ. TIMP 1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996; 2: 1369-1372.
11. Bolon I, Devouassoux M, Robert C, Moro D, Brambilla C, Brambilla E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol 1997; 150: 1619-1629.
12. Powe DG, Brough JL, Carter GI, et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997; 75: 1678-1683.
13. Wang M, Liu YE, Greene J, et al. Inhibition of tumour growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14: 2767-2774.
14. WHO. Histological typing of lung tumours. Am J Clin Pathol 1982; 77: 123-136.
15. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89 (Suppl): 225s-233s.
16. Tsao M-S, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 1997; 3: 1807-1814.
17. Takes PA, Kohrs J, Krug R, Kewley S. Microwave technology in immunohistochemistry: application to avidin biotin staining of diverse antigens. J Histotechnol 1989; 12: 95-98.
18. Hayashi T, Stetler-Stevenson WG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol 1996; 149: 1241-1256.
19. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613-622.
20. Freemont AJ, Byers RJ, Taiwo YO, Hoyland JA. In situ zymographic localization of type II collagen degrading activity in osteoarthritic human articular cartilage. Ann Rheum Dis 1999; 58: 357-365.
21. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP. Ras oncogene mediated induction of a 92 kDa metalloproteinase: strong correlation with the malignant phenotype. Biochem Biophys Res Commun 1988; 154: 832-838.
22. Collier IE, Wilhelm SM, Eisen AZ, et al. Ha-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem 1988; 263: 6579-6587.
23. Gingras MC, Finch JJ, Bowden GT, Wright JA, Greenberg AH. Transient alterations in the expression of protease and extracellular matrix genes during metastatic lung colonization by H-ras-transformed 10T1/2 fibroblasts. Cancer Res 1990; 50: 4061-4066.
24. Meade-Tollin LC, Boukamp P, Fusenig NE, Bowen CPR, Tsang TC, Bowden GT. Differential expression of matrix metalloproteinases in activated c-rasHa-transfected immortalized human keratinocytes. Br J Cancer 1998; 77: 724-730.
25. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogene upregulates VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis. Cancer Res 1995; 55: 4575-4580.
26. Sier CFM, Kubben FJGM, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417.
27. Hansen Ree A, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623-1628.
28. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-1659.
29. Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumour recurrence. Int J Cancer 1994; 59: 339-344.
30. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson WG, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995; 1: 899-906.
31. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298: 29-32.
32. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci 1994; 107: 2373-2379.